Consulta: creatorFacets:"Maciel,M.S."
Registros recuperados: 2
Data/hora: 02/06/2024 03:53:40

Sentinel node biopsy in breast cancer: results in a large series
Provedor de dados: Brazilian Journal of Medical and Biological Research
Autores: Carvalho,S.M.T.; Mourão Netto,M.; Lima,E.N.P.; Pimentel,A.M.; Makdissi,F.B.; Osório,C.A.B.T.; Maciel,M.S.; Iyeyasu,H.; Collins,J.B.; Fontes,C.M.; Perina,A.L.; Soares,F.A.
Sentinel lymph node biopsy (SLNB) is an appropriate method for the evaluation of axillary status in cases of early breast cancer. We report our experience in treating cases evaluated using SLNB. We analyzed a total of 1192 cases assessed by means of SLNB from July 1999 to December 2007. SLNB processing was successfully completed in 1154 cases with the use of blue dye or radiolabeled 99mTc-Dextran-500, or both. Of these 1154 patients, 857 were N0(i-) (no regional lymph node metastasis, negative immunohistochemistry, IHC), 96 were N0(i+) (no regional lymph node metastasis histologically, positive IHC, no IHC cluster greater than 0.2 mm) and 201 were N1mi (greater than 0.2 mm, none greater than 2.0 mm). Most of the tumors (70%) were invasive ductal carcinomas...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Breast neoplasms; Sentinel lymph node; Sentinel lymph node biopsy; Completion axillary dissection.
Ano: 2010
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010000600011

Gene expression profiling of clinical stages II and III breast cancer
Provedor de dados: Brazilian Journal of Medical and Biological Research
Autores: Folgueira,M.A.A.K.; Brentani,H.; Katayama,M.L.H.; Patrão,D.F.C.; Carraro,D.M.; Mourão Netto,M.; Barbosa,E.M.; Caldeira,J.R.F.; Abreu,A.P.S.; Lyra,E.C.; Kaiano,J.H.L.; Mota,L.D.; Campos,A.H.J.F.M.; Maciel,M.S.; Dellamano,M.; Caballero,O.L.S.D.; Brentani,M.M.
Clinical stage (CS) is an established indicator of breast cancer outcome. In the present study, a cDNA microarray platform containing 692 genes was used to identify molecular differences between CSII and CSIII disease. Tumor samples were collected from patients with CSII or CSIII breast cancer, and normal breast tissue was collected from women without invasive cancer. Seventy-eight genes were deregulated in CSIII tumors and 22 in CSII tumors when compared to normal tissue, and 20 of them were differentially expressed in both CSII and CSIII tumors. In addition, 58 genes were specifically altered in CSIII and expression of 6 of them was tested by real time RT-PCR in another cohort of patients with CSII or CSIII breast cancer and in women without cancer....
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Breast cancer; CDNA microarray; Clinical stage; Gene expression.
Ano: 2006
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000800013